Therapeutic approaches targeting the prion receptor LRP/LR.
Transmissible spongiform encephalopathies known as prion diseases are a group of fatal neurodegenerative disorders that affect both humans and animals. The generally accepted principle of the disease is that the conversion of the cellular prion protein (PrP(c)) into the disease associated isoform PrP(Sc) leads to spongiform degeneration of the brain and amyloid plaque formation. Until now no therapy leading to potential alleviation or even cure of the disease exists. It is therefore important to develop therapeutic approaches for the treatment of TSEs since these infections are inevitably fatal and, especially in the case of vCJD, they affect youngsters. Besides current conventional therapeutic strategies, this review summarizes new therapeutic tools targeting the prion receptor LRP/LR.
Zuber
Chantal
C
Laboratorium für Molekulare Biologie-Genzentrum, Institut für Biochemie der Ludwig-Maximilians-Universität München, Munich, Germany.
Ludewigs
Heike
H
Weiss
Stefan
S
D000818:Animals; D002417:Cattle; D007562:Creutzfeldt-Jakob Syndrome / Q000473:pathology / Q000628:therapy; D016643:Encephalopathy, Bovine Spongiform / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008970:Molecular Weight; D017096:Prion Diseases / Q000473:pathology / Q000628:therapy*; D011328:Prions / Q000378:metabolism / Q000502:physiology*; D011498:Protein Precursors / Q000378:metabolism / Q000502:physiology*; D017474:Receptors, Laminin / Q000378:metabolism / Q000502:physiology*
D011328:Prions; D011498:Protein Precursors; D017474:Receptors, Laminin